News
NXLIW
0.1270
+64.72%
0.0499
Weekly Report: what happened at NXLIW last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at NXLIW last week (0415-0419)?
Weekly Report · 04/22 09:47
BUZZ-U.S. STOCKS ON THE MOVE-Paramount Global, SES AI, Zhongchao
U.S. Stock index futures slip on Friday as investors turn risk-averse. Netflix falls in premarket trade after company forecast current-quarter revenue below estimates. Dow e-minis down 0.17% while Nasdaq 100 futures also down. Paramount Global, SES AI and Zhongchao are among the top percentage gainers.
Reuters · 04/19 12:03
Weekly Report: what happened at NXLIW last week (0408-0412)?
Weekly Report · 04/15 09:43
BUZZ-U.S. STOCKS ON THE MOVE-Ocugen, Model N, Fastly
Futures tracking Wall Street's main indexes were largely muted on Monday. Treasury yields rose on rising bets that the U.S. Federal Reserve could delay interest-rate cuts this year. Dow e-minis were up 0.13% in early trading. Ocugen up 9.8% on FDA approval of gene therapy for Parkinson's disease.
Reuters · 04/08 13:50
BUZZ-U.S. STOCKS ON THE MOVE- Ducommun, Tesla, Take-Two
U.S. Stock index futures were flat on Monday as Treasury yields rose. Dow e-minis down 0.01%. Ducommun, Tesla, Take-Two are among the top percentage gainers on the NYSE. Tesla up 2.2% after Musk to unveil 'Robotaxi' on August 8.
Reuters · 04/08 12:17
Weekly Report: what happened at NXLIW last week (0401-0405)?
Weekly Report · 04/08 09:45
NEXALIN TECHNOLOGY INC - AWARDED U.S. PATENT RELATING TO CO'S NON-INVASIVE, FREQUENCY-BASED DEEP BRAIN STIMULATION DEVICE
Reuters · 04/04 17:01
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
U.S. Patent No. 17/337,653 awarded to Nexalin Technology. The newly issued patent covers the method of use utilized in the Company’s Gen-3 HALO Clarity™ system. The patent covers a non-invasive, frequency-based deep brain stimulation device.
Barchart · 04/04 12:00
Weekly Report: what happened at NXLIW last week (0325-0329)?
Weekly Report · 04/01 09:45
Weekly Report: what happened at NXLIW last week (0318-0322)?
Weekly Report · 03/25 09:46
Weekly Report: what happened at NXLIW last week (0311-0315)?
Weekly Report · 03/18 09:45
Weekly Report: what happened at NXLIW last week (0304-0308)?
Weekly Report · 03/11 09:44
BUZZ-U.S. STOCKS ON THE MOVE-Silver miners, Albemarle, Pfizer
Federal Reserve Chair Jerome Powell says central bank expects to reduce benchmark interest rate later this year. The Dow Jones Industrial Average was up 0.28% at 38,694.64. Top three S&P 500 percentage gainers: Albemarle, DexCom, Pfizer.
Reuters · 03/06 19:09
BUZZ-U.S. STOCKS ON THE MOVE-Couchbase, Foot Locker, Nordstrom
Federal Reserve Chair Jerome Powell says central bank expects to reduce benchmark interest rate later this year. The Dow Jones Industrial Average was up 0.38% at 38,731.02. The top three S&P 500 percentage gainers were Hewlett Packard, Box and Nordstrom. Nordstrom, Couchbase and Ross Stores were among the biggest losers.
Reuters · 03/06 16:30
BUZZ- Nexalin rises on positive data for sleep disorder treatment device
Shares of medical equipment maker Nexalin Technology rise 15% to 40 cents premarket. Nexalin says its experimental device to treat chronic insomnia significantly reduced the severity of insomnia in adult patients. The device, Gen-2 tACS, was tested in 120 patients aged 22 to 65 years old.
Reuters · 03/06 14:10
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Nexalin announces positive results of a clinical study of its Gen-2 tACS device for the treatment of chronic insomnia. The study evaluated the treatment response of 120 adult participants in Beijing. Nexalin is developing a device to treat chronic insomnia with the help of a partner.
Barchart · 03/06 07:30
Weekly Report: what happened at NXLIW last week (0226-0301)?
Weekly Report · 03/04 09:45
Weekly Report: what happened at NXLIW last week (0219-0223)?
Weekly Report · 02/26 09:49
Weekly Report: what happened at NXLIW last week (0212-0216)?
Weekly Report · 02/19 09:50
More
Webull provides a variety of real-time NXLIW stock news. You can receive the latest news about Nexalin Tech through multiple platforms. This information may help you make smarter investment decisions.
About NXLIW
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.